{"id":"NCT01040728","sponsor":"Boehringer Ingelheim","briefTitle":"A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease","officialTitle":"Randomised, Double-blind, Double-dummy, Placebo-controlled, 4-way Cross-over Study to Characterise the 24-hour FEV1-time Profiles of BI 1744 CL 5μg and 10μg (Oral Inhalation, Delivered by the Respimat® Inhaler) and Tiotropium Bromide 18μg (Oral Inhalation, Delivered by the HandiHaler®) After 6 Weeks of Treatment in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-01","primaryCompletion":"2011-01","completion":null,"firstPosted":"2009-12-30","resultsPosted":"2014-06-30","lastUpdate":"2014-06-30"},"enrollment":122,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Pulmonary Disease, Chronic Obstructive"],"interventions":[{"type":"DRUG","name":"Olodaterol (BI1744) Low","otherNames":[]},{"type":"DRUG","name":"Olodaterol (BI1744) High","otherNames":[]},{"type":"DRUG","name":"Tiotropium 18 mcg","otherNames":[]},{"type":"DRUG","name":"Placebo (for Olodaterol (BI1744)l)","otherNames":[]},{"type":"DRUG","name":"Placebo (for Tiotropium)","otherNames":[]}],"arms":[{"label":"Olodaterol (BI1744) Low","type":"EXPERIMENTAL"},{"label":"Olodaterol (BI1744) High","type":"EXPERIMENTAL"},{"label":"Tiotropium 18 mcg","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The study is intended to characterize the lung function profile of BI1744 in Chronic Obstructive Pulmonary Disease (COPD) patients where patients will perform pulmonary function tests at regular intervals for 24 hours at the end of a 6 week treatment period. Each patient will receive all four treatments.","primaryOutcome":{"measure":"FEV1 Area Under Curve 0-12 h (AUC 0-12h) Response After Six Weeks of Treatment","timeFrame":"1 hour (h) and 10 minutes (min) prior to the am dose on the first day of the first treatment period (study baseline) and -30 min (zero time), 30 min, 60 min, 2 hour (h) , 3 h, 4 h, 6 h, 8 h, 10 h, 12 h relative to am dose after six weeks of treatment","effectByArm":[{"arm":"Placebo","deltaMin":-0.008,"sd":0.019},{"arm":"Olo 5 mcg qd","deltaMin":0.189,"sd":0.019},{"arm":"Olo 10 mcg qd","deltaMin":0.213,"sd":0.019},{"arm":"Tio 18 mcg qd","deltaMin":0.213,"sd":0.019}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"},{"comp":"OG000 vs OG002","p":"<0.0001"},{"comp":"OG000 vs OG003","p":"<0.0001"}]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":16},"locations":{"siteCount":12,"countries":["United States","Germany","Netherlands","Norway"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":109},"commonTop":["Nasopharyngitis","Chronic obstructive pulmonary disease"]}}